Sysmex's Own Numbers Disagree by Thirteen Point Eight Per Cent on the Size of the Market It Leads

Editorial analysis accompanying the Global Haematology and Coagulation Diagnostics Market Report, 2026–2033.

Sysmex publishes two numbers about haematology that cannot both be correct, and the gap between them is not a rounding error.

Its Integrated Report puts the global haematology field at USD 4,300 million and its own share at 54.6%, ranked first. Multiply those two disclosed numbers and you get a revenue figure: USD 2,348 million. Its actual disclosed haematology revenue for the year to March 2026 is JPY 299,407 million — which, at JPY 148 to the dollar, is USD 2,023 million.

The shortfall is USD 325 million. That is 13.8%.

Two readings, one number

There are exactly two ways to reconcile this, and they are arithmetically identical.

Either the market is 13.8% smaller than published — USD 3,705 million rather than USD 4,300 million, with Sysmex’s 54.6% share intact. Or the market is right and the share is 13.8% lower than published, at 47.0% rather than 54.6%.

Neither can be dismissed from outside the company. Share estimates are estimates; field definitions move; a share table assembled on one definition of the addressable field and a revenue line assembled on another will produce exactly this kind of gap. And a company that holds a genuine majority of a field and reports a number implying it does not is a company whose internal geography differs from its public one.

What can be said is narrower and more useful: the two figures are incompatible in one direction and by one magnitude, and any analyst quoting a haematology market size — including this one — is quoting a number whose only public derivation contradicts itself by 13.8%.

Why the disagreement is carried rather than resolved

The report uses USD 4,350 million for 2025 haematology — the published figure rolled forward — and treats the 13.8% as an explicit uncertainty band on the base instead of picking a side. That is a deliberate choice, and it has a cost: it means the headline number is knowingly imprecise.

The alternative is worse. Adopting the disclosed revenue and the published share would shrink the field by 13.8% and break the report’s reconciliation to the in vitro diagnostics hub, which puts the discipline at USD 7,620 million and 7.06% of a USD 108.0 billion base in 2025. Adopting the published market and discounting the share would contradict a revenue line filed in an audited statement. The band is the honest position; the resolution would be a preference dressed as arithmetic.

The mirror case: where a footnote dissolves the claim

The same discipline produces a cleaner answer in haemostasis, and the reason is a single clause.

Sysmex claims the number one position in haemostasis too. Its own footnote discloses that this ranking “includes sales through alliances” — its instruments reach a substantial part of the market under the Siemens Healthineers brand. Standalone, its haemostasis revenue of JPY 72,409 million is USD 489 million, which is 15.0% of a USD 3,270 million field.

Fifteen per cent is not a first place on revenue. Werfen’s attributed USD 1,200 million is 36.7%. Diagnostica Stago — the only pure-play haemostasis company in the world, EUR 550 million across 115 countries, ownership transferred in 2026 — holds 19.0%. The top three hold 70.5%, and there is still a visible fourth tier beneath them.

So the two halves of this discipline have genuinely different structures. Haematology has a monopoly. Haemostasis does not. And that difference, more than any technology argument, is why one grows at 3.31% and the other at 5.42%.

Why haematology can be audited at all

Attribution in this discipline is unusually clean: ten named vendors account for USD 6,684 million of a USD 7,620 million market — 87.72% — against a stated residual of USD 936 million, or 12.28%.

Every other report in this cluster carries a residual between 33% and 51%. Clinical chemistry sits at 51.1%, because anyone can make a buffer and a substrate and no unlisted producer has a reason to disclose. The reagent and consumable layer as a whole sits at 51.24%, for the same reason: a reagent is a recipe, and a recipe carries no filing obligation.

Here it is 12.28%, and that is not superior research. It is a fact about the product. A six-part differential is produced by a closed system — reagent, optics, the algorithm that classifies a scattergram, and the reference intervals the result is reported against, validated together. The buyer cannot substitute one component for another. A market with no unlisted middle is a market where every vendor’s revenue is visible.

The conclusion that follows, and it is uncomfortable

Visibility cuts both ways. A field whose revenue attributes to a short list of named vendors is a field a procurement authority can price precisely: it can see whom it is buying from and what they charge. The same property that makes the market auditable makes it tenders-able.

That is the mechanism behind the numbers. Anhui’s coagulation procurement took an average 40.16% off six items in January 2023, against a ceiling set from what the province’s hospitals had actually paid the previous year. Sysmex’s group operating margin then fell from 17.2% to 10.4% on a 1.7% decline in sales. The concentration did not protect the discipline from administered pricing. It made the discipline the obvious target.

Which is the real finding of the reconciliation, and the reason it is worth stating at this length: the 13.8% gap is not the interesting part of the arithmetic. The interesting part is that this is one of the few markets in diagnostics where the arithmetic can be checked at all — and that when it was checked, it did not close.

Companion analyses in this cluster

A second analysis on this market examines what CMS did to the complete blood count for 2027, and why the second-highest-volume code in the American fee schedule is reported inside a category that does not name its field: The Complete Blood Count Is the Second-Most-Ordered Test in America and Its Category Does Not Exist.

Related research: Global Haematology and Coagulation Diagnostics Market, 2026–2033; Global In Vitro Diagnostics Market; Global IVD Reagents and Consumables Market, where the residual is 51.24% for the mirror reason; and Global Clinical Chemistry and Urinalysis Market.

About the method

70% secondary, 30% primary. The secondary layer is Sysmex’s Integrated Report 2025 field and share table, its consolidated results and product-type revenue series for the year to March 2026, Werfen’s 2025 results, the ARCHIMED/La Caisse announcement for Diagnostica Stago, and the Anhui provincial procurement notice — each read from the issuing body. No market-research competitor material is cited, quoted or used to set any level.

The primary layer is 47 depth interviews across 13 markets, 29 open-ended interviews around tender cycles, a 176-respondent laboratory survey and structured observation at four conferences. It establishes mechanism only, carries no figure, and the counts are stated so they can be reconciled against programme records.

Conversions use JPY 148/USD, consistent with every other report in this cluster. The two readings of the gap are arithmetically identical; the report carries the band rather than resolving it by preference.

Sources

• Sysmex Corporation — Integrated Report 2025, field market size and share table
• Sysmex Corporation — Consolidated Financial Results, FY ended 31 March 2026
• Sysmex Corporation — Net Sales by Destination, Business and Product Type
• Werfen — Werfen reaches EUR 2.1 billion in sales (9 April 2026)
• ARCHIMED — ARCHIMED Diagnostics acquires Stago (29 April 2026)
• People’s Daily, Anhui — Anhui completes China’s first coagulation and cardiac-marker IVD reagent procurement (20 January 2023)

Company and entity links

Sysmex Q7663566 · Werfen Q16797700 · hematology Q103824 · hemostasis Q487937